BlueSky Vaccines is a clinical-stage biotech company known for its proprietary technology platform for interferon-inducing viral vectors (delNS). Their mission is to harness the power of immunostimulation and antiviral properties offered by interferons to develop next-generation immunotherapy against cancer and viral infectious diseases. BlueSky's delNS technology activates immunological defense reactions against cancer by stimulating the production of antiviral molecules and activating immune cells such as Natural Killer Cells, Cytotoxic T-Cells, Dendritic Cells, and Macrophages.

This technology makes tumors vulnerable to the immune system, opening up new possibilities for innovative and gentle cancer therapies. BlueSky Immunotherapies has achieved remarkable success with its viral vector platform delNS. They have demonstrated visible results in the therapy of equine sarcoids in horses, indicating the potential for easy-on-the-body cancer therapies in humans.

The company's cutting-edge technology has been widely published and has garnered recognition in peer-reviewed journals. BlueSky is currently conducting clinical trials to assess the efficacy of delNS for tumor elimination and prevention of cervical carcinoma and head and neck cancer. Additionally, their interferon-based approach shows promise in fighting infectious diseases, with successful tests against influenza viruses and COVID-19 in animal models.

With a team of experienced professionals and a commitment to innovation, BlueSky Vaccines is at the forefront of revolutionizing immunotherapy